Smoking status and response to thiopurines in steroid-dependent inflammatory bowel disease
Authors:
- Sílvia CarriónSCSílvia Carrión
- Esther Garcia-PlanellaEGEsther Garcia-Planella
- Míriam MañosaMMMíriam Mañosa
- Jordi GordilloJGJordi Gordillo
- Mar ConcepciónMCMar Concepción
- Carlos GuarnerCGCarlos Guarner
- Eduard CabréECEduard Cabré
- 1 April 2011
- journal article
- research article
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 17 (4) , 971-975
Abstract
The influence of smoking on inflammatory bowel disease (IBD) susceptibility and on its clinical course is well known, but not its impact on drug efficacy. The aim of this study was to evaluate the response to thiopurines in patients with steroid-dependent IBD according to their smoking habits. The medical records of 163 IBD patients (103 Crohn's disease [CD], 60 ulcerative colitis [UC]) in whom thiopurines were started because of steroid-dependency were reviewed. Therapeutic response was defined by steroid-free clinical remission for at least 6 months after 12 months of starting thiopurines. Clinical data and smoking status at diagnosis, at the time thiopurines were started, and during the follow-up were registered. A therapeutic response was obtained in 72% of CD and 61% of UC patients. Smoking habits did not influence the rate of response to thiopurines, the need for rescue therapies, or the development of penetrating/stricturing complications (CD) or proximal progression (UC). However, CD responders who continued smoking required new courses of steroids more often during follow-up. No influence of smoking was found when these outcomes were analyzed depending on gender or disease location. In the multivariate analysis, smoking status was the only predictive factor of drug tolerance. Active smoking does not influence the response to thiopurines in steroid-dependent IBD, but may decrease the likelihood of drug tolerance.Keywords
This publication has 29 references indexed in Scilit:
- Early azathioprine/biological therapy is associated with decreased risk for first surgery and delays time to surgery but not reoperation in both smokers and nonsmokers with Crohnʼs disease, while smoking decreases the risk of colectomy in ulcerative colitisEuropean Journal of Gastroenterology & Hepatology, 2010
- Novel pharmacogenetic markers for treatment outcome in azathioprine‐treated inflammatory bowel diseaseAlimentary Pharmacology & Therapeutics, 2009
- Perianal disease, small bowel disease, smoking, prior steroid or early azathioprine/biological therapy are predictors of disease behavior change in patients with Crohn’s diseaseWorld Journal of Gastroenterology, 2009
- Prospective evaluation of the pharmacogenetics of azathioprine in the treatment of inflammatory bowel diseaseAlimentary Pharmacology & Therapeutics, 2008
- Comparative effectiveness of azathioprine in Crohn’s disease and ulcerative colitis: prospective, long‐term, follow‐up study of 394 patientsAlimentary Pharmacology & Therapeutics, 2008
- The use of thiopurines for the treatment of inflammatory bowel diseases in clinical practiceDigestive and Liver Disease, 2008
- Infliximab Plus Azathioprine for Steroid-Dependent Crohn’s Disease Patients: A Randomized Placebo-Controlled TrialGastroenterology, 2006
- Thiopurine methyltransferase activity influences clinical response to azathioprine in inflammatory bowel diseaseClinical Gastroenterology and Hepatology, 2004
- Smoking in Crohn's disease: effect on localisation and clinical course.Gut, 1992
- Classification of Inflammatory Bowel DiseaseScandinavian Journal of Gastroenterology, 1989